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Abstract
Introduction: Dysregulated NOTCH receptor activity has been implicated in breast cancer but the mechanisms by
which NOTCH contributes to transformation are not yet clear, as it has context-dependent effects on the properties
of transformed cells.
Methods: We have used various in vitro and in vivo carcinogenic models to analyze the impact of Notch signaling
in the onset and progression of breast tumors.
Results: We found that ectopic expression of the Notch1 intracellular domain (N1ICD) in MCF-7 breast
adenocarcinoma cell line caused reduction and delocalization of E-CADHERIN levels and increased migratory and
invasive abilities. Notch inhibition in the invasive breast cancer cell line MDA-MB-231 resulted in increased
E-CADHERIN expression and a parallel reduction in their invasive capacity. The growth of subcutaneous xenografts
produced with MCF-7 cells was boosted after N1ICD induction, in a cell autonomous manner. In vivo Notch1
activation in the mammary gland using the MMTV-Cre driver caused the formation of papillary tumors that showed
increased Hes1 and Hey1 expression and delocalized E-cadherin staining.
Conclusions: These results confirm NOTCH1 as a signal triggering epithelial-mesenchymal transition in epithelial
cancer cells, which may have implications in tumor dissemination, metastasis and proliferation in vivo. The
identification of specific factors interacting with NOTCH signaling could thus be relevant to fully understanding the
role of NOTCH in breast neoplasia.
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Introduction
Notch is a fundamental signaling pathway that regulates
embryonic cell fate specification, proliferation and pattern-
ing [1,2]. In addition to its central role in development,
Notch signaling is deregulated in a number of cancers [3].
Notch1 mutations lead to oncogene expression in certain
T cell acute lymphoblastic leukemias [4] and a subset of
breast carcinomas [5]; deregulated Notch activity might
also affect cell transformation [6], regulation of the cell
cycle [7], progenitor/stem cell maintenance [3] and the
outcome of breast cancer [8].
The mammalian Notch proteins (Notch1 to 4) are
membrane-bound type I receptors with a large extracell-
ular domain involved in ligand binding, and a cytoplasmic
domain responsible for signal transduction. The Notch
ligands Delta-like 1, 3 and 4 and Jagged 1 and 2 are also
membrane-bound. Ligand-receptor interactions between
neighboring cells trigger Notch signaling, which leads to a
sequence of proteolytic cleavage events in the receptor.
The last of these is mediated by g-secretase activity, gener-
ating the Notch intracellular domain (NICD), which trans-
locates to the nucleus and binds the CSL transcription
factor. The NICD/CSL complex induces expression of
target genes, including those of the hairy/enhancer of split
(Hes) family [1,2], the cell cycle regulator p21 [9] and
cyclin D1 [7].
Many studies focus on the role of Notch1 in mammary
tumorigenesis. Hyperactivated Notch1 signaling was first
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implicated in mammary tumorigenesis in studies of the
MMTV model, which showed that N1ICD expression in
MMTV-Neu mammary tumors is due to an MMTV inser-
tion in the Notch1 locus [10]. Other reports indicated that
transgenic activation of N1ICD in mammary glands leads
to development of lactation-dependent tumors that regress
at weaning [11,12]. These findings link aberrant Notch
activation in the murine mammary gland to adenocarci-
noma. Experimental evidence shows that altered Notch1
signaling leads to direct transcriptional regulation of
c-myc, which is crucial in MMTV-N1ICD-induced murine
mammary tumorigenesis [13]. NOTCH1 is also involved
in human mammary tumorigenesis as a downstream
effector of oncogenic Ras [14].
Here we used various in vitro and in vivo models to ana-
lyze the impact of Notch signaling in breast tumor onset
and progression. We find that stable or inducible N1ICD
expression in the poorly invasive MCF-7 breast adenocar-
cinoma cell line causes a reduction and delocalization of
E-CADHERIN levels, suggesting a disassembly of adherens
junctions that correlates with enhanced cell migratory and
invasive abilities. These properties may be extended to
other epithelial tumor cell lines as we have made similar
observations in the colon cancer cell line HT-29 stably
expressing N1ICD. To the contrary, Notch inhibition in
the highly invasive cell line MDA-MB-231 resulted in
increased E-CADHERIN expression and a parallel reduc-
tion in their invasive capacity. Notch1 activation in the
mouse mammary gland using the MMTV-Cre driver
caused the formation of papillary tumors that showed
increased Hes1 and Hey1 and delocalized E-cadherin
expression. We also found that the growth of subcuta-
neous xenografts produced with MCF-7 cells was
boosted after N1ICD induction, in a cell autonomous
manner. These results confirm Notch1 as an epithelial-
to-mesenchymal transition (EMT) inducer in breast
cancer cells, which may have implications in tumor
dissemination and metastasis.
Methods
Cell lines
The human breast cancer cell lines MCF-7 (ATCC®
HTB-22™) and MDA-MB-231 (ATCC® HTB-26™),
and the human colorectal adenocarcinoma cell line
HT-29 (ATCC® HTB-38™) were used. For culture con-
ditions see Additional file 1, Supplementary Materials
and methods.
Transfection of MCF-7 and HT-29 cells
A cDNA fragment encoding the active version of mouse
Notch1 (N1ICDΔOP) was used [15]. The Tet-Off system
was employed to obtain transfectants of MCF-7 with
inducible N1ICD expression. In this system, gene
expression is turned on when doxycycline (DOXY; a tet-
racycline derivative) is removed from the culture med-
ium. For details see Additional file 1, Supplementary
Materials and methods.
Western blot analysis
For details see Additional file 1, Supplementary Materials
and methods.
Semi-quantitative RT-PCR and real-time quantitative PCR
Total RNA was extracted with Trizol reagent (Life
Technologies, NY, USA) and cDNA was synthesized
with SuperScript III First Strand kit (Life Technologies,
NY, USA). N-Cadherin primers were 5´-CACCCAA-
CATGTTTACAATCAACAATGAGAC-3 (forward) and
5´-CTGCAGCAACAGTAAGGACAAACATCCTATT-3
(reverse) [16]. Commercial b-actin primers were used
(Stratagene, La Jolla, CA, USA). Quantitative PCR was per-
formed with Power SYBR Green Master Mix (Applied
Biosystems, NY, USA, 4367659) and commercial primers
for HEY1, HES1, cMYC, NOTCH1, NOTCH4, SNAI1,
ECAD, VIMENTIN and HPRT1 (Sigma, St. Louis, MO,
USA) were used.
Promoter activity assays
Hes1-Luc promoter activity [17] was measured in MCF-7
cells expressing N1ICD in a constitutive or inducible man-
ner. The activity of the artificial promoter 10XCBF1 [18]
was measured after transient transfection of MDA-
MB-231 cells. Briefly, cells were co-transfected with the
plasmid containing the promoter 10XCBF1-Luc and
pcDNA3-CBF1-VP16 or pcDNA3-DN-CBF1/RBPJK. The
plasmid pTK-RL (Promega, Madison, WI, USA) was
also included as a control of transfection efficiency. When
indicated, cells were treated for the indicated period
of time with DOXY 2 μg/ml or with the g-Secretase
Inhibitors DAPT (N-(N-(3,5-Difluorophenacetyl)-L-ala-
nyl)-S-phenylglycine t-butyl ester, 10 to 50 μM; 565770,
Calbiochem, Millipore, MA, USA) and RO4929097 ((2,2-
dimethyl-N-(S)-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-
7-yl)-N’-(2,2,3,3,3-pentafluoro-propyl)-malonamide)), 10
to 20 μM; S1575, Selleckchem, Houston, TX, USA) for
48 h. After transfection cells were lysed with passive lysis
buffer (Promega, Madison, WI, USA) and firefly and
renilla luciferase were measured with the “Dual-luciferase
reporter assay” (Promega, Madison, WI, USA). The activ-
ity in MCF-7 clones or in MDA-MB-231 treated cells was
referred to the activity in control cells or cells transfected
with the empty vector (pcDNA3).
Immunofluorescence and immunohistochemistry
For details see Additional file 1, Supplementary Materials
and methods.
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In situ hybridization
In situ hybridization was performed as described in [19].
Details of probes will be provided on request.
In vitro cell chemotaxis
Cell migration was performed in Transwell (Corning,
Tewksbury, MA, USA) with 8 μm pore filters coated
with 20 μg/ml collagen type IV (Sigma, St. Louis, MO,
USA). Cells were pretreated for the time indicated with
DOXY (MCF-7) or DAPT/RO4929097/DMSO (MDA-
MB-231), trypsinized and added to the upper chamber
in basal medium with 0.5% BSA and the additives. The
lower chamber was replenished with basal medium with
BSA and the chemoattractant (IGF-1, 50 ng/ml, R&D
Systems, Minneapolis, MN, USA or SDF1a, PeProTech
(New Jersey, USA). After 18 h incubation, the upper
chamber was emptied and cells remaining are removed.
Cells in the filter are fixed with PFA and then stained
with violet crystal (Sigma-Aldrich). Cell counts were
obtained by counting two (MDA-MB-231) or four
(MCF-7) grids using a microscope fitted with a grid eye-
piece at a total magnification of 100X.
Flow cytometry
For details see Additional file 1, Supplementary Materials
and methods.
In vivo experiments with mice
All animal procedures were approved by the Institutional
Committee for the Care and Use of Laboratory Animals of
the Centro Nacional de Investigaciones Cardiovasculares
(CNIC, Madrid, Spain) and Centro Nacional de Biotecno-
logía (CNB-CSIC, Madrid, Spain). Animal procedures
conformed to EU Directive 2010/63EU and Recommenda-
tion 2007/526/EC, regarding the protection of animals
used for experimental and other scientific purposes,
enforced in Spanish law under Real Decreto 1201/2005.
Tumorigenic assays
MCF-7/TetOff and B12, M5 and M20 derivatives’ clones,
growing in culture without DOXY for 25 days, were
inoculated s.c in both flanks (1.5 or 2.4 × 106 cells)
in BALBc/SCID mice treated with 17a-ethylenestradiol
1 μg/ml (Sigma) provided in the drinking water from one
week before cells were injected. Tumor size was moni-
tored weekly and tumor volume estimated with a caliper
by measuring the width (a) and the length (b) and applying
the formula (a2 × b)/2. Once finished with the period of
treatment, mice were sacrificed and tumors were extracted
for further analysis. MCF-7/TetOff and B12 were trans-
duced with recombinant retrovirus to express luciferase
activity. Plasmid pRV-luc-IRES-CopGreen was used to
obtain the retroviral supernatants (Genetrix S.L., Madrid,
Spain) and transduced cells were sorted according to the
associated green fluorescence. BALBc/SCID mice (Harlan
Laboratories, Indianapolis, IN, USA) were injected in the
two inguinal mammary glands with 2.5 × 106 cells and
mice were treated as above. After injection, half of the
mice were treated also with DOXY 2 mg/ml provided in
the drinking water. Tumoral growth rate was analyzed by
bioluminescence at different weeks after cell inoculation.
Briefly, mice were injected with luciferin with the general
anesthetic and luciferase activity expressed by cells was
detected with a CCD camera placed in a dark box (Hama-
matsu Photonics, Shizuoka, Japan). Images were processed
with the software provided and luminescence units were
represented. Tumor size was estimated as above and once
finished with the period of treatment, tumors were
excised, weighted and preserved adequately to make
further analysis.
Transgenic N1ICD expression in the mammary gland
The transgenic lines MMTV-Cre [20] and Rosa26N1ICD
[21] were bred to generate MMTV-Cre/+; Rosa26N1ICD/
+ double transgenic mice. For primers and conditions of
mouse genotyping see [20,21]. Mice were subjected to
several rounds (a median of four) of pregnancy and lacta-
tion, and when a breast tumor arose, mice were eutha-
nized and the breast tumor excised and processed for
further analysis. Tumor samples were fixed with 10% buf-
fered formalin (Sigma-Aldrich) for 48 h and afterward
were paraffin-embedded. Staining of Hes1, ERa, p63,
E-cadherin and Ki67 was performed in 5 μm sections of
paraffin samples following standard techniques. For details
see Additional file 1, Supplementary Materials and
methods.
Results
N1ICD expression enhances the invasive capacity of the
breast cancer cell line MCF-7
To gain an insight into the role of Notch in breast cancer
we used the breast cancer cell line MCF-7 that has several
features of differentiated mammary epithelium [22]. These
cells show low levels of N1ICD expression by Western
blot when compared with the metastatic breast cancer cell
line MDA-MB-231 (Figure 1A). This observation fits with
the idea that high NOTCH signaling is associated with the
expression of basal breast cancer markers [23].
We generated MCF-7 clones stably expressing a myc-
tagged N1ICD version (Figure 1B). MCF-7 cells have
a typical cobblestone phenotype (not shown) and express
the epithelial cell marker E-CADHERIN (Figure 1B, C).
N1ICD expression caused a reduction in total
E-CADHERIN levels in MCF-7 clones E8 and F7 but not
in clone F5 (Figure 1B, C). The levels of Notch activity in
MCF-7/N1ICD cells measured by a luciferase reporter
assay using a fragment of the mouse Hes1 promoter [17],
revealed an evident activation of the Notch pathway in
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Figure 1 Stable N1ICD expression induces migration of MCF-7 cells. (A) Western blot showing expression of endogenous N1ICD in MCF-7
and MDABM231 cells. SMC3 (Structural Maintenance of Chromomosomes-3 protein) was used as a loading control. (B) Expression of N1ICD and
E-CADHERIN in the stable MCF-7 clones E8, F5 and F7 besides with mock MCF-7 cells; b-ACTIN was used as a loading control. (C) The Western blot in
(B) was quantified by densitometry and the ratio of E-CADHERIN/b-ACTIN calculated. (D) NOTCH activity was determined with a Hes-1 promoter
fragment. The value in the clones is represented relative to the value in mock cells. Data are mean ± SEM of quadruplicates in three independent
experiments (*P <0.05 determined by Student’s t test). (E) Expression of HEY1, HES1, C-MYC, SNAI1, VIMENTIN, E-CADHERIN and NOTCH1 in the stable
MCF-7 clones E8 and F7, measured by qPCR. Data are mean ± SEM of triplicates in two independents experiments (*P <0.05, ***P <0.001 determined
by Student’s t-test). (F) Staining of N1ICD (red), E-CADHERIN (green) and nuclei (DAPI, blue) in E8 and F5 MCF-7-N1ICD clones. Arrows indicate the
intercellular staining of E-CADHERIN and arrowheads its intracellular accumulation. (G, H) Effect of ectopic N1ICD expression on the chemotaxis of E8
and F5 MCF-7 cell clones. (G) Representative images of transmigrated cells in basal (-IGF-1) and after IGF-1 addition (+IGF). (H) Quantification of the
transwell assays. The migration index was calculated for each condition, and then referred to that of mock (considered as 1). Data are mean ± SEM of
triplicates in three independent experiments (*P <0.05 determined by Student’s t test). DAPI, 4,6-Diamidino-2-phenylindol; MCF-7, Michigan Cancer
Foundation-7 breast cancer cell line; N1ICD, Notch one intracellular domain
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comparison with control, mock-transfected MCF-7
cells (Figure 1D). qPCR analysis revealed a marked up-
regulation of the NOTCH target genes HEY1, HES1 and
C-MYC while the epithelial marker E-CADHERIN was
down-regulated and SNAIL1 and VIMENTIN were not
significantly changed (Figure 1E). We also examined
NOTCH1 and NOTCH4 expression because of their role
in mouse breast cancer malignancy [24] and their overex-
pression in triple-negative breast cancer subtypes [25].
NOTCH4 expression was almost undetectable in MCF-7
cells (Additional file 2, Figure S1A) while NOTCH1
expression was unaffected (Additional file 2, Figure S1B
and not shown), as previously reported [26].
Semi-quantitative RT-PCR analysis of various MCF-7-
N1ICD expressing clones revealed no variation in JAG1
and TWIST1 expression (Additional file 2, Figure S1B).
The lack of response of TWIST1 to N1ICD expression is
in agreement with previous findings showing that during
developmental EMT, Twist1 is induced by Bmp2 [27] but
does not respond to Notch [28]. Immunofluorescence
analysis confirmed that forced N1ICD expression caused
a reduction in membranous E-CADHERIN staining
(Figure 1Fa-i). Cells with strong nuclear N1ICD staining
showed mostly nuclear E-CADHERIN expression, sug-
gesting a disassembly of adherens junctions [29], which
contrasted with its accumulation in the membrane at the
cell-cell contacts of MCF-7 cells that did not express
N1ICD (Figure 1Fe). Concomitant to the reduction in
E-CADHERIN levels, N1ICD expression endowed MCF-7
cells with increased chemotactic ability towards IGF-1
(Figure 1G, H), a chemo-attractant for this cell line [30];
some N1ICD-expressing MCF-7 clones showed an
increased migratory capacity, even in basal medium
(Figure 1Gb, c). To test if the reduction of E-CADHERIN
upon N1ICD expression could be extended to other
epithelial tumor cell lines, we transfected N1ICD into the
HT-29 colon adenocarcinoma cell line and generated
stable clones. We chose HT-29 cells because, similarly to
the mammary gland, they derive from a tissue in which
NOTCH has an oncogenic role [31,32]. Additional file 3,
Figure S2A, B shows that HT-29 cells stably expressing
N1ICD down-regulate E-CADHERIN expression.
Inducible N1ICD expression in MCF-7 cells leads to
E-cadherin down-regulation and increased migratory
capacity
To study more precisely the effect of Notch expression
in MCF-7 cells, we generated N1ICD-inducible clones
using the TetOFF system, so that gene expression was
induced when the antibiotic doxycycline (DOXY) was
removed from the culture medium. Figure 2A shows
N1ICD-myc staining of three inducible clones (B12, M5
and M20) cultured in the presence (OFF condition) or
absence (ON condition) of DOXY. There was some
leaky N1ICD expression in the OFF condition in these
three clones (especially for B12; Figure 2Aa-f), but 48 h
after DOXY withdrawal there was a clear induction of
N1ICD expression (Figure 2Ag-l), although not in 100%
of the cells. Examination after seven days of induction
also revealed a non-homogenous N1ICD expression in
these MCF-7 clones (data not shown).
The effect of DOXY retrieval in N1ICD induction was
measured by luciferase assay upon transfection of a
Hes1 reporter. There was clear reporter activation after
N1ICD induction in the different clones studied, espe-
cially in clone B12 at 48 h (Figure 2B). This enhanced
N1ICD-induced transcriptional activity correlated with
the increase of N1ICD expression in the different clones
upon doxycycline withdrawal (Figure 2C). Concomi-
tantly to N1ICD induction, there was an increase in the
migratory capacity of these cells (Figure 2D, E).
To investigate the possible correlation between the
enhancement in the migratory capacity of MCF-7-TetOFF-
N1ICD clones and the reduction of E-CADHERIN expres-
sion in these cells, we performed an immunofluorescence
analysis of clones M5, M20 and B12 after 20 days of
culture in the absence of DOXY. Induction of N1ICD
expression coincided with a reduction of membranous
E-CADHERIN staining in these clones (Figure 3A-D).
Western blot analysis after 20 days of induction revealed a
marked reduction in E-CADHERIN expression in clone
B12 that was not so apparent in clones M5 and M20
(Figure 3E). We then carried out a time-course of N1ICD
repression/induction in clone B12 and its effect on
E-CADHERIN expression. As Figure 3F shows, there was
an inverse correlation between N1ICD and E-CADHERIN
expression. MCF-7-TetOFF-N1ICD cells of clone B12 cul-
tured seven days in the absence of DOXY showed strong
N1ICD expression (Figure 3F). After one day in culture in
the presence of DOXY, N1ICD expression was progres-
sively reduced and in parallel, E-CADHERIN expression
was increased throughout seven days of culture (Figure
3F). To the contrary, when cells from clone B12 were
grown in the absence of DOXY, N1ICD expression was
increased and E-CADHERIN expression was reduced, and
this effect was clear after seven days of culture without
DOXY (Figure 3F).
These data indicated that N1ICD expression in MCF-7
cells, either in an inducible or stable manner, leads to
a reduction in E-CADHERIN levels, suggesting that these
cells began to lose their epithelial phenotype. During
EMT there is a progressive cadherin switch, such that
E-cadherin expression is reduced and N-cadherin expres-
sion is increased [33]. Figure 3G shows a semi-quantitative
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Figure 2 Inducible N1ICD overexpression in MCF-7 cells promotes a migratory behavior. (Aa-f) General view of the MCF-7 Tet-Off clones
(B12, M5 and M20) cultured in the presence of DOXY. a-c, anti-myc staining reveals leaky myc-N1ICD expression; d-f, anti-myc and DAPI staining
overlapping. (Ag-l) General view of these clones cultured in the absence of DOXY. g-i, anti-myc staining reveals N1ICD induction in these cells;
j-l, anti-myc and DAPI staining. (B) Quantification of Hes1 promoter activity in MCF-7 uninduced and induced clones. Data are mean ± SEM of
quadruplicates in three independent experiments (**P <0.005 determined by Student’s t-test). (C) Western blot analysis of myc-N1ICD expression
in MCF-7 control cells and MCF-7 clones after seven days of culture with or without DOXY. (D) Representative images of transmigrated cells in
basal (-IGFI) and IGF-I supplemented (+IGF) cells. (a, b) control, (c, d) N1ICD-induced B12 and (e, f) M5 MCF-7 cells. (E) The relative migration
index for each cell type is represented. Data are mean ± SEM of duplicates in three independent experiments (*P <0.05, **P <0.005 determined
by Student’s t test). DAPI, 4,6-Diamidino-2-phenylindol; DOXY, doxycycline; MCF-7, Michigan Cancer Foundation-7 breast cancer cell line; N1ICD,
Notch one intracellular domain
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RT-PCR analysis of N-CADHERIN expression in clone
B12. Upon DOXY withdrawal there was a progressive
increase in N-CADHERIN expression that was at a maxi-
mum after seven days of culture (Figure 3G, H), suggesting
that B12 cells acquired a mesenchymal phenotype.
Moreover, we found that N1ICD induction enhanced
VIMENTIN expression although it did not change Twist1
mRNA levels (Additional file 4, Figure S3).
NOTCH inhibition reduces the migratory ability of MDA-
MB-231 cells
To gain further insights on the role of NOTCH in
breast tumor progression and the potential use of
NOTCH inhibitors as therapeutic agents against breast
cancer, we inhibited NOTCH activity in the adenocarci-
noma cell line MDAMB-231 [34], which is more
tumorigenic and invasive than the MCF-7 cell line.
Figure 3 E-CADHERIN and N-CADHERIN levels are modified in MCF-7 cells by overexpression of N1ICD. (A) Immunofluorescence staining
of E-CADHERIN expression (red) in MCF-7 Tet-Off cells. (B-D) E-CADHERIN staining is lost in some cells where N1ICD (green) is induced. Nuclei
are counterstained with DAPI (blue). (E) Western blot analysis of E-CADHERIN in MCF-7 mock and MCF-7 inducible clones in the presence (blue)
or absence (black) of doxyxycline. (F) Time-course analysis of E-CADHERIN expression by Western blot after DOXY addition and depletion in
clone B12. (G, H) N-CADHERIN transcription measured by RT-PCR in clone B12 after DOXY depletion. DAPI, 4,6-Diamidino-2-phenylindol; DOXY,
doxyxycline; MCF-7, Michigan Cancer Foundation-7 breast cancer cell line; N1ICD, Notch one intracellular domain
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MDA-MB-231 cells endogenously expressed N1ICD
(Figures 1A and 4A) and E-CADHERIN levels in
MDA-MB-231 were reduced compared to those of
MCF-7 cells (Additional file 5, Figure S4). We used the
g-secretase inhibitors DAPT [35] and RO4929097 [36],
to prevent the generation of NICD and thus inhibit
Notch activity. After 48 h we could readily detect a
drastic reduction in N1ICD levels in DAPT- and RO-
treated cells (Figure 4A). This effect could also be mea-
sured by the reduction in the activity of a CBF1 reporter
(Figure 4B). NOTCH inhibition also resulted in an up-
regulation of E-CADHERIN paralleled by a reduction in
HES1 expression (Figure 4C). The migratory response of
MDA-MB-231 cells towards IGF-1 was reduced around
80% when cells were cultured with DAPT or RO (Figure
4D, E). MDA-MB-231 cells were also transfected with a
dominant-negative version of CBF1 (DN-CBF1); we
observed a 25% reduction in the migratory capacity of
DN-CBF1-expressing MDA-MB-231 cells compared to
controls (Figure 4F). The weaker inhibition of migration
in comparison with the DAPT or RO treatments was
likely due to the fact that MDA-MB-231 cells were tran-
siently transfected and only a subpopulation expressed
the DN-CBF1 construct (data not shown).
Inducible Notch1 activation in MCF-7 cells stimulates
tumor growth in vivo
To examine the tumorigenic ability of MCF-7-N1ICD
inducible clones we focused on the B12 clone as it showed
a clear phenotypic change as a consequence of N1ICD
induced overexpression. Growth of MCF-7 xenografts is
estrogen-dependent [37], so we injected MCF-7-Tet-Off-
N1ICD B12 cells and added 17a-ethynyl estradiol to the
drinking water. When small size tumors were evident in
all injection points, mice were divided into two groups. In
the first group N1ICD expression was “turned on” (no
DOXY) and in the second one, N1ICD expression was
turned “Off” by addition of DOXY to the drinking water.
As Figure 5A shows, the tumors in which N1ICD expres-
sion was turned off did not grow significantly, while
tumors in which N1ICD expression was maintained for 12
weeks continued growing and were significantly larger
than those generated by control MCF-7 (data not shown)
or by un-induced cells (Figure 5A). After 12 weeks, treat-
ments were switched between both groups of mice (Figure
5A, arrow), and tumors were monitored for seven weeks
more. The result was a reduction in the differences
between both groups, leading to similar tumor size
(Figure 5A). Thus, tumor growth was clearly dependent
on turning “On” or “Off” N1ICD expression.
The growth curves shown in Figure 5A, B suggest also
that estrogens may be a limiting factor in Notch-mediated
tumor formation and growth. Western blot analysis of
xenografts generated after 12 weeks of N1ICD induction
revealed strong N1ICD expression (Figure 5C).
Next, we analyzed growth of orthotopic tumors formed
by the clone B12 transduced with a luciferase-expressing
retrovirus to monitor tumor evolution by chemoluminis-
cence. After cell injection, mice were separated in two
groups, receiving (N1ICD off) or not (N1ICD on) DOXY
in the drinking water. In agreement with our previous
results (Figure 5A), clone B12 with induced N1ICD
expression gave rise to tumors significantly larger than
those generated when N1ICD was not expressed (Figure
5D, E). DOXY treatment did not affect the growth of
tumors formed by control MCF-7 cells (Figure 5D, F).
These results suggested that N1ICD induction might be
directly responsible for MCF-7 tumor formation.
N1ICD expression in the mammary gland leads to tumor
formation and reduction in estrogen receptor and E-
cadherin expression
To test in vivo the effect of NOTCH activation in the
mammary gland we bred the mouse mammary tumor
virus (MMTV)LTR-Cre transgenic line (MMTV-Cre) [20]
with the Rosa26N1ICD line that expresses the active form
of Notch1 (N1ICD) in a conditional manner [21]. With
the MMTV-Cre driver we targeted N1ICD expression to
the secretory epithelium of the mammary gland of
pregnant and lactating females. MMTV-Cre/+;N1ICD/+
double transgenic mice developed normally and were born
at Mendelian ratios (data not shown). Adult MMTV-
Cre/+; N1ICD/+ females showed high incidence of papil-
lary breast carcinoma (>90%; Additional file 6, Table S1).
Figure 6A shows a wildtype lactating breast, with greatly
expanded secretory lobules composed of multiple dis-
tended acini. Figure 6B, C shows papillary tumors devel-
oped in lactating transgenic females (V004 and V006)
after three to four rounds of pregnancy and lactation.
Tissue architecture was disorganized and large necrotic
areas were observed (Figure 6B). Also, frequent mitotic
figures and cytological atypia were common (Figure 6C,
inset). We analyzed the expression of the Notch targets
Hes1 and Hey1, estrogen receptor, the myoepithelial
marker p63, which stains basal/myopithelial preserved
cells in normal or non-malignant breast tissue [38], the
epithelial marker E-cadherin and the cell proliferation
marker Ki67. Hes1 expression was low and restricted to a
few cells in normal breast epithelial tissue (Figure 6D), like
that of estrogen receptor (Figure 6E), while p63 stained
around 30% of cells, as expected for a normal tissue
(Figure 6F). E-cadherin was strongly expressed in the
membrane of normal breast epithelial cells (Figure 6G).
Ki67 was expressed only in a few cells in the normal breast
(Figure 6H) and Hey1 was undetectable (Figure 6I). In the
tumors generated in double transgenic MMTV-Cre;
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Figure 4 NOTCH signaling inhibition decreases the migratory behavior of MDA-MB-231 cells. (A) Western blot showing Notch
one intracellular domain (N1ICD) expression in MDA-MB-231 cells after 48 h of treatment with DAPT or RO4929097 (RO). Equal amounts of
protein loading were validated with an anti-SMC3 antibody. (B) Notch activity measured with the 10 × CBF1 reporter. The value for DAPT and
RO4929097 treated cells is relative to the activity in cells treated with DMSO. Data are mean ± SEM of quadruplicates in three independent
experiments (*P <0.05, **P <0.005 determined by Student’s t-test). (C) Representative images of migration towards IGF-1 50 ng/ml of MDA-
MB-231 cells with DAPT or RO4929097 or the vehicle DMSO. (D) Migration index obtained in both conditions. Data are mean ± SEM of
duplicates in three independent experiments (***P <0.001 determined by Student’s t-test). (E) Migration index quantification of MDA-MB-231
cells transfected with an empty vector (pCDNA3) or a dominant negative version of CBF1 (DN-CBF1) towards IGF-1 (50 ng/ml). Data are
mean ± SEM of duplicates in three independent experiments (*P <0.05 determined by Student’s t-test). CBF1, CSL, Suppressor of Hairless; DAPT,
N-(N-(3,5-difluorophenacetyl)-l-alanyl)-S-phenylglycine t-butyl ester; DMSO, dimethyl sulfoxide; MCF-7, Michigan Cancer Foundation-7 breast
cancer cell line; MDA-MB-231, Breast cancer cell line derived from metastatic site (pleural effusion); N1ICD, Notch one intracellular domain
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Figure 5 N1ICD induction promotes a tumorigenic behavior. (A) Growth of xenografts derived from MCF-7 B12 clone with induced N1ICD
(-Doxy) or without N1ICD (+Doxy) expression. Mice also had 17a-ethynyl estradiol (+EE2) in the drinking water. The arrow indicates the 12th week
when DOXY treatment was switched between both groups of mice. (B) Growth of N1ICD-induced B12 cells in the absence of estrogen (+EE2)
administration. The arrow indicates the week 12th when DOXY treatment was switched. Data are mean ± SEM of n = 8 (four mice and two tumors per
mice; *P <0.05 determined by two-way ANOVA with Bonferroni post-test). (C) Western blot showing expression of myc-tagged N1ICD in B12 tumors at
12th week of cell inoculation. (D) MCF-7 Tet-Off or the MCF-7 B12 clone engineered to express luciferase injected in the mammary gland of BALBc/
SCID mice were monitored by bioluminescence emission at the time of cell inoculation and after 12 weeks as indicated. Selected images of two
independents experiments, four animals per group. (E) Growth dynamics measured by luminescence of MCF-7 B12 clone with (-DOXY) or without
(+DOXY) N1ICD expression. (F) Growth of control MCF-7 clones in the same conditions. Data are mean ± SEM of n = 8 (four mice and two tumors per
mice; ***P <0.001 determined by two-way ANOVA with Bonferroni post-test), representative of two independents experiments. DOXY, doxyxycline;
MCF-7, Michigan Cancer Foundation-7 breast cancer cell line; N1ICD, Notch one intracellular domain
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Figure 6 MMTV-Cre; N1ICD transgenic mice develop papillary tumors. (A-C) H&E stainings; (D-H, J-N, P-T, V-Z) immunostainings; (I, O,
U, A’) in situ hybridization. In (D-G, J-M, P-S,V-Y), sections are counterstained with toluidine blue; in (H, N, T, Z) sections are counterstained with
Mayer’s Hematoxylin. (A) Normal lactating breast. Greatly expanded secretory lobules (arrows) containing milky secretion are surrounded by
breast epithelium (small arrows). Adipose tissue containing lipid vesicles (asterisk) is also abundant. (B) Transgenic female V004. Tumor tissue
coexisting with normal tissue is demarcated by a blue dashed line. Breast architecture is widely disorganized. (C) Transgenic female V006. Large
necrotic areas (yellow dash line) are observed. Inset shows mitosis (arrows) in tumor tissue. (D) Hes1 expression (brown nuclei, arrow) is rare in
normal breast epithelium. Asterisk indicates milky secretion. (E, F) estrogen receptor (brown nuclei, arrows in E) and p63 expression (brown
nuclei, arrows in F) in normal breast epithelium. (G) E-cadherin expression in the membrane of breast epithelial cells. (H) Few signs of
proliferation in normal lactating breast as indicated by Ki67 staining in only a few cells (brown nuclei, arrows). (I) Normal lactating breasts show
no Hey1 expression. (J-O) V006 transgenic female. Tumor area is demarcated by a red dashed line. Note the increased Hes1 expression (J, brown
nuclei, arrows). (K) estrogen receptor expression (arrows). (L) p63 expression is observed in the non-pathological tissue (arrow) surrounding the
tumor. (M) E-cadherin is expressed in membrane of epithelium. (N) Proliferation can be observed throughout the tumor by Ki67 staining (brown
nuclei, arrows). (O) Expression of Hey1 in tumor tissue (arrow). (P-U) V015 transgenic female. Normal tissue is demarcated by green dashed line.
(P) Hes1 expression is strongly up-regulated in tumor cells. (Q) Estrogen receptor (arrows) expression is more widespread. (R) p63 expression is
very reduced in tumor tissue. (S) E-cadherin is expressed in membrane (arrow) but also in cytoplasm (arrowheads) of tumor cells. (T) Strong
proliferation shown by Ki67 staining (arrows). (U) Hey1 expression in tumor (arrows). (V-A’) V093 transgenic female. (V) Widespread Hes1
expression in tumor (brown nuclei, arrows). Estrogen receptor (W, arrows) and p63 expression (X, arrows) in tumor. (Y) E-cadherin expression in
tumor (arrows). (Z) Strong proliferation in tumor shown by Ki67 staining (arrows). (A’) Expression of Hey1 in tumor (arrow).
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N1ICD mice (Additional file 6, Table S1) three patterns
could be distinguished. The first one, represented by
female V006 showed moderate but widespread Hes1
expression (Figure 6J), moderate estrogen receptor stain-
ing (Figure 6K), undetectable p63 expression (Figure 6L),
normal E-cadherin distribution (Figure 6M), and a marked
up-regulation of Ki67 and Hey1 expression (Figure 6N, O)
in the tumor area. The second one, exemplified by female
V015, showed strong and widely distributed Hes1 expres-
sion (Figure 6P), relatively high estrogen receptor expres-
sion (Figure 6Q) and undetectable p63 expression
(Figure 6R) in the tumor. E-cadherin was found in both
membrane and cytoplasm (Figure 6S), while Ki67 and
Hey1 expression was strong (Figure 6T, U). The third pat-
tern was represented by female V093, in which Hes1
expression was widespread but not as much as in the
V015 female (Figure 6V), moderate estrogen receptor
expression (Figure 6W), very low or absent p63 staining
(Figure 6X), with relatively normal E-cadherin expression
(Figure 6Y) and Ki67 and Hey1 expression was moderate
(Figure 6Z, A’). In general, our data showed that Hes1 and
Hey1, as markers of Notch1 activation in epithelial tissues,
coexisted with higher estrogen receptor expression. These
results are compatible with those obtained with the xeno-
grafts of inducible MCF-7-N1ICD cells, whose growth was
dependent on N1ICD and estrogens (Figure 4A, B). This
observation, together with the fact that tumors were only
observed after three to four pregnancies, suggested that
the involvement of Notch in breast tumor formation was
strongly dependent on estrogens and that Notch expres-
sion could lead to changes in estrogen receptor expression.
Discussion
There is considerable recent interest in understanding
how NOTCH signaling affects the development or pro-
gression of breast cancer. Notch is critical in mammary
gland development, probably by regulating mammary
stem cell function [39]. In addition, NOTCH activity
has been associated with a number of pro-tumorogenic
activities in breast cancer cell lines, and could cause
mammary hyperplasia and carcinogenesis in mice
[11,40-42]. This evidence strongly pinpoints NOTCH
receptors and/or ligands as targets in breast cancer.
Here we used three different in vitro and in vivo models
to analyze the impact of NOTCH signaling in the onset
and progression of breast tumors. We found a positive
association of NOTCH activity with cancer growth or
initiation. In agreement with others [43-46], one of the
most consistent observations along our study was the
association between NOTCH1 activity and E-CADHERIN
down-regulation. First, stable expression of activated
Notch (N1ICD) was associated with a reduction and
delocalization of E-CADHERIN in most of the MCF-7
cell clones analyzed; second, the data with the inducible
MCF-7-N1ICD clone B12 clearly established a causal
relationship between active NOTCH1 and reduced
E-CADHERIN levels; third, inhibition of endogenous
NOTCH activation with DAPT in MDA-MB-231 cells, a
highly invasive cell line that expresses high NOTCH1
levels, resulted in an increase of E-CADHERIN expression;
and fourth, papillary tumors raised in MMTV-Cre/+;
N1ICD/+ transgenic mice expressing high levels of Hes1
also showed, at least, a delocalization of E-cadherin in
the epithelium. Repression and/or delocalization of
E-CADHERIN is usually associated with adherens junc-
tions disassembly [29] and enhanced cell invasiveness [33].
Concurrently, we observed that N1ICD-induced
E-CADHERIN repression correlates with enhanced
motility in transwell assays, whereas inhibition of Notch
signaling, either by DAPT or RO inhibitors treatment or
DN-CBF1 overexpression, reduced the motility of the
invasive MDA-MB-231 cells. Collectively, these results
indicate that NOTCH1 activation could induce EMT in
epithelial tumor cells and, consequently, to favor tumor
metastasis [47].
The role of Notch as a critical inducer of EMT has been
demonstrated during the formation of the cardiac valve
primordium [48]. In this process, Notch activates Snail
expression that in turn down-regulates VE-cadherin [48].
We analyzed Snail1 expression in the MCF-7 clones
expressing N1ICD, and found no clear correlation among
N1ICD expression, E-CADHERIN down-regulation and
SNAIL1 expression. We observed a markedly increased
HES1 and HEY1 expression in response to NOTCH1 acti-
vation that correlated with a reduction in E-CADHERIN
expression in both our cellular and animal models. Inter-
estingly, both HES1 and HEY1 have been implicated as
part of the hypoxic response associated to breast cancer
progression [45].
We also analyzed whether NOTCH1 affects the growth
and/or the onset of breast tumors. NOTCH signaling reg-
ulates the balance between cell proliferation, differentia-
tion and apoptosis [2] and different reports have
demonstrated that NOTCH triggers the proliferation of
breast cancer cells [46,49]. In line with these observations,
we found that the growth of subcutaneous and orthotopic
xenografts produced with MCF-7-B12 cells was boosted
after the induction of N1ICD (Figure 5). This effect was
cell autonomous, since silencing of N1ICD-expressing
tumors by administration of DOXY stopped the growth of
tumors whereas induction of N1ICD by DOXY withdrawal
boosted tumor growth, with kinetics compatible with
N1ICD induction.
Although induction of N1ICD in MCF-7 fosters tumor
growth, this effect was only observed when mice were
treated with estrogens; indeed, MCF-7 xenografts did not
grow in the absence of estrogens, independently of the
induction of N1ICD. These results suggest that N1ICD
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cooperates with the estrogen receptor (ER) on tumor
growth, as recently reported [50]. In agreement with this
conclusion, MMTV-Cre/+;N1ICD/+ mice only developed
mammary tumors after repeated pregnancies. It is note-
worthy to mention that these breast tumors appeared in
the lactating gland and regressed after gland involution;
the regression was independent of N1ICD activity as
determined by the Hes1 expression level. Our results thus
resemble those obtained by Kiaris et al. [11], and contrast
with the formation of non-regressing mammary neoplasm
in transgenic mice expressing the active forms of Notch1,
-3 and -4, reported by others [12,41,42]. In summary, our
results confirm NOTCH1 as an EMT inducer in breast
cancer cells, which may have implications in tumor
growth, dissemination and metastasis. The identification
of specific factors interacting with NOTCH signaling
could thus be relevant to fully understand the role of
NOTCH in breast neoplasia.
Conclusions
NOTCH1 activation attenuates E-CADHERIN expression
and favors the motility and invasive ability of epithelial
human breast cancer MCF-7 cells in vitro. In xenografts
and in transgenic mice, NOTCH1 activation caused
tumors whose increased growth is NOTCH- and estrogen
receptor-dependent. To the contrary, NOTCH inhibition
leads to increased E-CADHERIN expression and attenu-
ates the migratory properties of invasive MDA-MB-231
breast cancer cells. Our findings in these mammary tumor
models point to NOTCH1 as a potential therapeutic target
in breast cancer onset and progression.
Additional material
Additional file 1: Supplementary Materials and Methods.
Additional file 2: Figure S1. NOTCH4 expression in the stable MCF-7
clones E8 and F7 compared to the mock MCF-7 cells, measured by qPCR.
cDNA of HUVEC cells was used as positive control of NOTCH4 expressing
cells. Data are mean ± SEM of triplicates in two independents
experiments (***P<0.001 determined by student’s t test).
Additional file 3: Figure S2. (A) Western Blot showing the expression of
N1ICD and E-cadherin in the stable HT-29 clones E11, E12, G12 and G9
compared with mock HT-29 cells; b-actin was used as loading control.
(B) Western Blot was quantified by densitometry and the ratio of
E-CADHERIN/b-ACTIN was calculated and referred to the mock cells.
Additional file 4: Figure S3. The inducible clone MCF-7-B12 shows
increased VIMENTIN expression while TWIST1 is unaffected upon N1ICD
induction. (A) Western blot showing inducible N1ICD expression in MCF-
7-B12 cells cultured in the presence (+Doxy) or absence (-Doxy) of
doxycycline. VIMENTIN expression is increased. (B) Semiquantitative RT-
PCR showing that TWIST1 transcription does not change after 7 days of
N1ICD induction.
Additional file 5: Figure S4. E-CADHERIN analysis of MCF-7 and MDA-
MB-231 cells by flow cytometry. (A) E-CADHERIN staining of MCF-7 cells
(black line) and MDA-MB-231 cells (dotted line) is shown. Ten-fold
reduction of the mean fluorescence intensity (MnIX) is shown. Gray
graph correspond to the staining of both cell lines with the
corresponding IgG1 isotype control. (B) Raw data of the MCF-7 analysis
(right) compared to the negative control (left). (C) Raw data of the MDA-
MB-231 analysis (right) compared to the negative control. Note that
there is a ten-fold reduction both in the staining intensity but also in the
number of MDA-MB-231 cells staining for E-CADHERIN (79.6%) in
comparison with MCF-7 (99.4%).
Additional file 6: Table S1. Breast tumor formation in MMTV-Cre/+;
N1ICD/+ females.
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